Climb Bio, Inc.
$10.44
-6.8%Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -11.9).
Valuation inputs: P/E -11.9, earnings yield N/A, momentum -6.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -37.3%, ROIC -42.2%).
Profitability stack: net margin 0.0%, ROE -37.3%, ROIC -42.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +4.3%, momentum -6.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Climb Bio, Inc. Market vs Earnings Trajectory
Performance Analysis
EPS Growth
Declining earnings warrant investigation into business challenges and competitive position.
Price-EPS Relationship
Price is rising despite declining earnings—caution advised as valuation may be stretched.
Stock Price Change
Over the 1Y period, stock price has increased by 709.3%.
P/E Ratio (TTM)
Relatively low P/E may indicate undervaluation or lower growth expectations.
Key Insight
Despite declining earnings (-11.4%), the stock price has risen (+709.3%). This disconnect suggests investors may be optimistic about future turnaround, but earnings recovery is critical to sustain the valuation.
Climb Bio, Inc. Fair Value Envelope
No Revenue Data
CLYM has not reported any revenue values in the available annual periods.
Climb Bio, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
CLYM has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
CLYM has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
CLYM has not reported any net profit margin values in the available annual periods.
Climb Bio, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Climb Bio, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Climb Bio, Inc. Street Expectations Map
Wall Street analysts project that CLYM stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 20.00, with estimates ranging from a low of 17.00 to a high of 25.00.
The consensus 1-year price target stands at 20.00, with estimates ranging from a low of 17.00 to a high of 25.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Climb Bio, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.14M and sold $1.85M worth of CLYM shares, resulting in $713K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
321.7K
779.62K
150.0K
879.38K
-100K
-$100K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
280.0K
361.20K
621.9K
974.69K
-613K
-$613K
Top Buyers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$831K
Levin Andrew David
Director
$52K
Thomas Stephen Basil
Director
$52K
Williams Douglas E
Director
$52K
Dunn Judith
Director
$52K
Top Sellers
Wilson Perrin Megan
Officer: Chief Business Officer
$948K
Thomas Stephen Basil
Director
$879K
Brennan Aoife
Director, Officer: President And Ceo
$25K
Pimblett Emily
Officer: Svp, Finance & Cao
$2K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $713K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Insider Participation
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
No Dividend Yield Data
CLYM has not reported any dividend yield values in the available annual periods.
clym Dividend History
Learning Layer
Related Guides
Build conviction on CLYM by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.